Homocysteine and fibrinogen changes with L-thyroxine in subclinical hypothyroid patients

Journal of Korean Medical Science

Volumn 22, Issue 3, 2007, Pages 431-435

  Çakal, Başak ^a   Çakal, Erman ^b   Demirbaş, Berrin ^b,c   Özkaya, Mesut ^b   Karaahmetoǧlu, Selma ^a   Serter, Rüştü ^b   Aral, Yalçin ^b  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b Department of Endocrinology and Metabolism ^*  (Turkey)

^c NONE   (Turkey)

Author keywords

Homocysteine and fibrinogen; Hypothyroidism

Indexed keywords

EID: 34447121370     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2007.22.3.431     Document Type: Article

References (34)

1. Mc Demott MT, Ridgeway EC. Subclinical hypothyroidism is mild thyroid failure and should be treated. J Clin Endocrinol Metab 2001; 86: 4585-90.
2. Canalis GJ, Manowitz NR, Mayor G, Ridgeay EC. The Colorado thyroid disease prevalence study. Arch Intern Med 2000; 16: 526-34.
3. Cantürk Z, Çetinarslan B, Tarkun İ, Cantürk NZ, Özden M, Duman C. Hemostatic system as a risk factor for cardiovascular disease in women in subclinical hypothyroidism. Thyroid 2003; 13: 971-7.
4. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: The Rotterdam Study. Ann Intern Med 2000; 132: 270-8.
5. Lien EA, Nedrebo BG, Varhaug JE, Nygard O, Aakvaag A, Ueland PM. Plasma total homocysteine levels during short term iatrogenic hypothyroidism. J Clin Endocrinol Metab 2000; 85: 1049-53.
6. Nedrebo BG, Nygard O, Ueland PM, Lien EA. Plasma total homocysteine in hyper- and hypothyroid patients before and during 12 months of treatment. Clin Chem 2001; 47: 1738-41.
7. Chadarevian R, Bruckert E, Leenhardt L, Giral P, Ankri A, Turpin G. Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism. J Clin Endocrinol Metab 2001; 86: 732-7.
8. Chadarevian R, Bruckert E, Giral P, Turpin G. Relationship between thyroid hormones and fibrinogen levels. Blood Coagul Fibrinol 1999; 10: 481-6.
9. Myrup B, Bregengard C, Faber JF. Primary haemostasis in thyroid disease. J Intern Med 1995; 238: 59-63.
10. Nedrebo B, Ericsson UB, Ueland PM, Refsum H, Lien EA. Plasma levels of the atherogenic aminoacid homocysteine in hyper- and hypothyroid patients. Eur J Endocrinol 1994; 130: 147.
11. Diekman MJ, Van der Put NM, Blom HJ, Tijssen JG, Wiersinga WM. Determinants of changes in plasma homocysteine in hyperthyroidism and hypothyroidism. Clin Endocrinol 2001; 54: 197-204.
12. Nedrebo BG, Ericsson UB, Nygard O, Refsum H, Ueland PM, Aakvaag A. Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. Metabolism 1998; 47: 89-93.
13. Hussein WI, Green R, Jacobsen DW, Faiman C. Normalization of hyperhomocysteinemia with L-thyroxine in hypothyroidism. Ann Intern Med 1999; 131: 348-51.
14. Barbe F, Klein M, Chango A, Fremont S, Gerard P, Weryha G, Gueant JL, Nicolas JP. Homocysteine, folate, vitamin B12, and transcobalamins in patients undergoing successive hypo-and euthyroid states. J Clin Endocrinol Metab 2001; 86: 1845-6.
15. Morris MS, Bostom AG, Jacques PF, Selhub J, Rosenberg IH. Hyperhomocysteinemia and hypercholesterolemia associated with hypothyroidism in the third US National Health and Nutrition Examination Survey. Atherosclerosis 2001; 155: 195-200.
16. Homocysteine Lowering Trialists. Collaboration lowering blood homocysteine with folic acid based supplements: meta-analysis of randomized trials. BMJ 1998; 316: 894-8.
17. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270: 2693-8.
18. Lindeman RD, Romero LJ, Schade DS, Wayne S, Baumgarter RN, Garry PJ. Impact of subclinical hypothyroidism on serum total homocysteine concentrations, the prevalence of coronary heart disease (CHD), and CHD risk factors in the New Mexico elder healt survey. Thyroid 2003; 13: 595-600.
19. Luboshitzky R, Aviv A, Herer P, Lavie L. Risk factors for cardiovascular disease in women with subclinical hypothyroidism. Thyroid 2002; 12: 421-5.
20. Atabek ME, Pirgon O, Erkul I. Plasma homocysteine concentrations in adolescents with subclinical hypothyroidism. J Pediatr Endocrinol Metab 2003; 16: 1245-8.
21. Deicher R, Vierhapper H. Homocysteine: a risk factor for cardiovascular disease in subclinical hypothyroidism? Thyroid 2002; 12: 733-6.
22. Sengul E, Cetinarslan B, Tarkun I, Canturk Z, Turemen E. Homocysteine concentrations in subclinical hypothyroidism. Endocr Res 2004; 30: 351-9.
23. Perez E, Cubero JM, Sucunza N, Ortega E, Arcelus R, Espinosa JR, Lianos OJ, Vaca FB. Emerging cardiovascular risk factors in subclinically hypothyroidism: Lack of change after restoration of euthyroidis. Metab 2004; 53: 1512-5.
24. Ozcan O, Cakir E, Yaman H, Akgul EO, Erturtk K, Beyhan Z, Bilgi C, Erbil MK. The effects of thyroxine replacement on the levels of serum asymmetric dimethylarginine (ADMA) and other biochemical cardiovascular risk markers in patients with subclinical hypothyroidism. Clin Endocrinol 2005; 63: 203-6.
25. Lowe GD, Wood DA, Douglas JT, Riemersma RA, Macintyra CC, Takase T, Tuddenham EG, Forbes CD, Elton RA, Oliver MF. Relationships of plasma viscosity, coagulation and fibrinolysis to coronary risk factors and angina. Thromb Haemost 1991; 65: 339-43.
26. Thomson WD, Smith EB. Atherosclerosis and coagulation system. J Pathol 1989; 159: 97-106.
27. Nolsom AR. Epidemiology of fibrinogen Eur Heart J 1995; 6: 21-3.
28. Müller B, Tsakiris DA, Roth CB, Guglielmetti M, Staub JJ, Marbet GA. Haemostatic profile in hypothyroidism as potential risk factor for vascular or thrombotic disease. Eur J Clin Invest 2001; 31: 131-7.
29. Diekman MJ, Anghelescu N, Endert E, Bakker O, Wiersinga WM. Changes in plasma low density lipoprotein and high density lipoprotein cholesterol in hypo and hyperthyroid patients are related to changes in free thyroxin, not to polymorphisms in LDL receptor or cholesterol ester transfer protein genes. J Clin Endocrinol Metab 2000; 85: 1857-63.
30. Bauer DC, Ettinger B, Browner WS. Thyroid function and serum lipids in older women: a population based study. Am J Med 1998; 104: 546-51.
31. Arem R, Patsch W. Liporotein and apolipoprotein levels in subclinical hypothyroidism. Effects of levothyroxine therapy. Arch Intern Med 1990; 150: 2097-100.
32. Caron P, Calazel C, Parra HJ, Hoff M, Louvet JP. Decreased HDL cholesterol in subclinical hypothyroidism : the effect of levothyroxine therapy. Clin Endocrinol 1990; 33: 519-23.
33. Meier C, Staub JJ, Roth CB, Guglielmetti M, Kunz M, Miserez AR, Drewe J, Huber P, Herzog R, Muller B. TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: A double blind, placebo controlled trial (basel thyroid study). J Clin Endocrinol Metab 2001; 86: 4860-8.
34. Serter R, Demirbas B, Korukluoglu B, Culha C, Cakal E, Aral Y. The effect of L-Thyroxine replacement therapy on lipid based cardiovascular risk in subclinical hypothyroidism. J Endocrinol Invest 2004; 27: 897-903.